Amplitude Modulated Radiofrequency Electromagnetic Field Treatment Combined With Radiochemotherapy and Maintenance Chemotherapy in Patients With Glioblastoma (Brain-RF)

Combined chemoradiation and radiofrequency electromagnetic field treatment for patients with glioblastoma

Trial Details

NCT ID
NCT06140875
Phase
NA
Sponsor
Charite University, Berlin, Germany
Status
RECRUITING
Cancer Type
Brain Cancer
Interventions
  • Radiofrequency electromagnetic field treatment
Locations (sample)
  • Berlin, Germany|52.52437,13.41053

Key Eligibility Criteria

  • Pathological evidence of newly diagnosed glioblastoma according to WHO classification criteria
  • Patients 18 to 70 years of age with a WHO performance status of 2 or less
  • All patients must sign written informed consent
  • Adequate hematologic, renal, and hepatic function (absolute neutrophil count, ≥1,5 x 103/μL; platelet count, ≥100 x 103/μL; serum creatinine ≤1.7 m…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Brain Cancer Trials on Trialify →